My recent Letter to the Editor of the New York Times in response to the Op-Ed piece decrying the cost of cancer treatments: Your recent editorial about the high cost of cancer drugs missed a number of very significant points which must be considered. Yes, newly developed cancer drugs are expensive, but when treatments like [...]
We dodged a bullet… for now! I’m pleased to report that the House just approved the FY12 DoD Appropriations Bill by a vote of 331-83. No amendments were offered to reduce or eliminate CDMRP (the Department of Defense Medical Research Program) funding. At this time we have managed to maintain the funding for the Prostate [...]
Yesterday there was an amendment passed on the House floor to restore the Prostate Cancer Research Program's 2012 funding to $80 million. The Department of Defense (DoD) Appropriations Bill (H.R. 2219) originally was slated to allocate only $64 million to the Prostate Cancer Research Program (PCRP), a 20% reduction from last year’s funding. Restoring these [...]
Darryl, the Malecare Executive Director, posted an organizational response to yesterday's New York Times Article on the newly approved advanced prostate cancer drugs and their economic impact. I thought that I would share his insightful post with everyone. "We can easily price commodities and drugs to whatever the market will bare, but how do we [...]
Today’s New York Times carried a front page article about the high cost of the new prostate cancer treatments. This article seems to be the talk of the town and the talk (based on the comments that have been entered on-line) has been anything but positive. Unfortunately, many of the comments have made with the [...]